Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-acting combination of cabotegravir plus rilpivirine: A picture of potential eligible and ineligible HIV-positive individuals from the Italian ARCA cohort.
Cervo A, Russo A, Di Carlo D, De Vito A, Fabeni L, D'Anna S, Duca L, Colpani A, Fois M, Zauli B, Mancarella G, Carraro A, Bezenchek A, Cozzi-Lepri A, Santoro MM; ARCA Study Group. Cervo A, et al. J Glob Antimicrob Resist. 2023 Sep;34:141-144. doi: 10.1016/j.jgar.2023.07.006. Epub 2023 Jul 13. J Glob Antimicrob Resist. 2023. PMID: 37453495 Free article.
Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort.
d'Arminio Monforte A, Tavelli A, Rossotti R, Gagliardini R, Saracino A, Lo Caputo S, Sala M, Quiros-Roldan E, Mussini C, Girardi E, Cozzi-Lepri A, Antinori A, Puoti M; NoCo Study of the Icona cohort. d'Arminio Monforte A, et al. Liver Int. 2023 Oct;43(10):2130-2141. doi: 10.1111/liv.15700. Epub 2023 Aug 31. Liver Int. 2023. PMID: 37649460 Free article.
Determinants of worse liver-related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort.
d'Arminio Monforte A, Tavelli A, Salpini R, Piermatteo L, D'Anna S, Carrara S, Malagnino V, Mazzotta V, Brancaccio G, Marchetti GC, Rosselli Del Turco E, Rossotti R, Mussini C, Antinori A, Lo Caputo S, Ceccherini Silberstein F, Gaeta GB, Svicher V, Puoti M; Icona Foundation Study Group. d'Arminio Monforte A, et al. Liver Int. 2024 Feb;44(2):603-613. doi: 10.1111/liv.15804. Epub 2023 Dec 15. Liver Int. 2024. PMID: 38100128 Free article.
Impact of COVID-19 pandemic on retention in care of native and migrant people with HIV in the ICONA cohort.
Gagliardini R, Giacomelli A, Bozzi G, D'Arminio Monforte A, Tavelli A, Mazzotta V, Bruzzesi E, Cervo A, Saracino A, Mussini C, Girardi E, Cozzi-Lepri A, Antinori A; ICONA Foundation study group. Gagliardini R, et al. Among authors: cervo a. Travel Med Infect Dis. 2024 Mar-Apr;58:102691. doi: 10.1016/j.tmaid.2024.102691. Epub 2024 Feb 8. Travel Med Infect Dis. 2024. PMID: 38336335 Free article.
Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors.
Clemente T, Galli L, Lolatto R, Gagliardini R, Lagi F, Ferrara M, Cattelan AM, Focà E, Di Biagio A, Cervo A, Calza L, Maggiolo F, Marchetti G, Cenderello G, Rusconi S, Zazzi M, Santoro MM, Spagnuolo V, Castagna A; PRESTIGIO Study Group. Clemente T, et al. Among authors: cervo a. BMJ Open. 2024 Feb 10;14(2):e080606. doi: 10.1136/bmjopen-2023-080606. BMJ Open. 2024. PMID: 38341206 Free PMC article.
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort.
d'Arminio Monforte A, Tavelli A, Di Biagio A, Sarmati L, Marchetti GC, Bai F, Cingolani A, Quiros Roldan E, Mussini C, Lichtner M, Vergori A, Piconi S, Orofino G, Fusco FM, Bandera A, Nozza S, Castagna A, Antinori A; ICONA Foundation Study Group. d'Arminio Monforte A, et al. J Antimicrob Chemother. 2024 Apr 6:dkae081. doi: 10.1093/jac/dkae081. Online ahead of print. J Antimicrob Chemother. 2024. PMID: 38581349
Risk of virological failure after drug burden reduction in people with 4-class drug-resistant HIV on virological suppression: a retrospective cohort analysis of data from the PRESTIGIO Registry.
Clemente T, Diotallevi S, Lolatto R, Gagliardini R, Giacomelli A, Fiscon M, Ferrara M, Cervo A, Calza L, Maggiolo F, Rusconi S, Santoro MM, Castagna A, Spagnuolo V; PRESTIGIO Study Group. Clemente T, et al. Among authors: cervo a. Int J Antimicrob Agents. 2024 May 9:107195. doi: 10.1016/j.ijantimicag.2024.107195. Online ahead of print. Int J Antimicrob Agents. 2024. PMID: 38734216 No abstract available.
Efficacy of bezlotoxumab in preventing the recurrence of Clostridioides difficile infection: an Italian multicenter cohort study.
Meschiari M, Cozzi-Lepri A, Cervo A, Granata G, Rogati C, Franceschini E, Casolari S, Tatarelli P, Giacobbe DR, Bassetti M, Pinna SM, De Rosa FG, Barchiesi F, Canovari B, Lorusso C, Russo G, Cenderello G, Cascio A, Petrosillo N, Mussini C. Meschiari M, et al. Among authors: cervo a. Int J Infect Dis. 2023 Jun;131:147-154. doi: 10.1016/j.ijid.2023.04.004. Epub 2023 Apr 7. Int J Infect Dis. 2023. PMID: 37030653 Free article.
Vancomycin resistant enterococcus risk factors for hospital colonization in hematological patients: a matched case-control study.
Meschiari M, Kaleci S, Monte MD, Dessilani A, Santoro A, Scialpi F, Franceschini E, Orlando G, Cervo A, Monica M, Forghieri F, Venturelli C, Ricchizzi E, Chester J, Sarti M, Guaraldi G, Luppi M, Mussini C. Meschiari M, et al. Among authors: cervo a. Antimicrob Resist Infect Control. 2023 Nov 13;12(1):126. doi: 10.1186/s13756-023-01332-x. Antimicrob Resist Infect Control. 2023. PMID: 37957773 Free PMC article.
60 results